Q-omics provides the consensus-scored RHBG profile across patient tissues and cancer cell-line models. RHBG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RHBG is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RHBG RNA expression shows 13,561 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where RHBG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHBG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHBG survival associations across molecular data types. RHBG RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHBG RNA expression–survival associations across cancer types. High RHBG expression shows unfavorable associations in KIRP, KIRC, ACC, LGG and DLBC, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RHBG RNA expression.
This table summarizes RHBG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RHBG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHBG shows lower tumor expression in KIRC, HNSC and KIRP and higher tumor expression in LUAD, BLCA and BRCA. The KIRC box plot shows higher RHBG RNA expression in normal versus tumor tissue (log2 FC = −3.726, t-test p < 0.001).
This table shows molecular features associated with RHBG in patient tissues and cancer cell lines. In patient samples, RHBG shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RHBG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and CNS.
